Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Taysha Gene Therapies Inc
TSHACurrent price
1.76 USD
-0.06 USD (-3.30%)
Last closed
1.82 USD
Company
www.tayshagtx.com
ISIN
US8776191061
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
373 200 128 USD
Yield for 12 month
-28.16 %
1Y
3Y
5Y
10Y
15Y
TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. Address: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.55 USDP/E ratio
–Dividend Yield
–Current Year
+8 333 000 USD
Last Year
+15 451 000 USD
Current Quarter
+2 022 000 USD
Last Quarter
+1 788 000 USD
Current Year
+8 333 000 USD
Last Year
+15 451 000 USD
Current Quarter
+2 647 000 USD
Last Quarter
+1 788 000 USD
Key Figures TSHA
1 year
3 years
5 years
10 years
EBITDA
-85 376 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-32.51 %
PEG Ratio
–
Return On Equity TTM
-121.94 %
Wall Street Target Price
6.55 USD
Revenue TTM
8 333 000 USD
Book Value
0.35 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-43.90 %
Dividend Yield
–
Gross Profit TTM
8 333 000 USD
Earnings per share
-0.36 USD
Diluted Eps TTM
-0.36 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TSHA
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History TSHA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation TSHA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
35.68
Price Sales TTM
44.79
Enterprise Value EBITDA
-0.61
Price Book MRQ
5.22
Financials TSHA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TSHA
For 52 weeks
1.05 USD
4.32 USD
50 Day MA
1.57 USD
Shares Short Prior Month
25 248 849
200 Day MA
1.93 USD
Short Ratio
9.98
Shares Short
21 631 407
Short Percent
13.92 %
BeatStart